Evogen Moves Into Molecular Diagnostics With Initial Focus on Epilepsy

Dec 09, 2016

Premium

NEW YORK (GenomeWeb) – Biotech firm Evogen is moving from its traditional focus on infectious disease threat detection to precision medicine and molecular diagnostics, with a primary emphasis on neurology.

The company's first product in this area is the EvoScore START test, a blood-based proteomic assay intended to help doctors distinguish epileptic seizures from seizures with other causes. According to Todd Wallach, Evogen's president and CEO, the company plans to launch the diagnostic in targeted markets as a laboratory-developed test in 2017.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Menu